[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368514-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368514-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prospects-for-parg-inhibitors-in-cancer-therapy","Prospects for PARG inhibitors in cancer therapy","","Review article examining the enzyme poly(ADP-ribose) glycosylhydrolase (PARG) and the development of PARG inhibitors for cancer therapy. It explains how PARG hydrolyzes ribose–ribose bonds in poly(ADP-ribose) and works with PARP to regulate PAR levels, thereby influencing DNA maintenance and repair. The review summarizes evidence of elevated PARG across multiple cancer types and highlights PARG as a significant PAR-related molecular target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prospects-for-parg-inhibitors-in-cancer-therapy/368514/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prospects-for-parg-inhibitors-in-cancer-therapy/368514.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does PARG play in ADP-ribosylation?","Question",{"text":63,"@type":64},"PARG hydrolyzes ribose–ribose bonds in poly(ADP-ribose) (PAR), helping regulate PAR levels in cells. This process is connected to DNA maintenance and repair.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are PARG inhibitors considered promising for cancer therapy?",{"text":68,"@type":64},"Elevated PARG levels have been reported in several cancers, and PARG is described as a significant molecular target for treating PAR-related cancers. Targeting PARG may affect PAR dynamics that support harmful cancer outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the PARylation cycle relate to PARG activity?",{"text":72,"@type":64},"PARylation formation and dissociation are dynamically regulated, with PAR being largely degraded by PARG at DNA damage sites. This transient regulation helps maintain cellular functions and genome stability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368514,1790195071,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Journal of Molecular Cell Biology (2024), 16(11), mjae050 [https://doi.org/10.1093/jmcb/mjae050](https://doi.org/10.1093/jmcb/mjae050)  \nPublished online December 12, 2024  \nReview  \nProspects for PARG inhibitors in cancer therapy  \nYangchan Hu1 , 2 , Yuxin Meng1 , 2 , Zirui Zhuang2 ,3 , Yuancong Li1 , 2 , Junjun Nan1 , 2 , Ning Xu4 , Zu Ye5 ,6 , * , and Ji Jing 2 ,6 , *  \n1 College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China  \n2 Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China  \n3 School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences (UCAS), Hangzhou 310024, China  \n4 Institute of Drug Development & Chemical Biology, College of Pharmaceutical Science, Zhejiang University of Technology, Huzhou 313200, China  \n5 Gastric Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HlM), Chinese Academy of Sciences, Hangzhou 310022, China  \n6 Zhejiang Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer, Hangzhou 310022, China  \n* Correspondence to: Ji Jing, [E-mail:](E-mail: jingji@him.cas.cn)[ jingji@him.cas.cn](E-mail: jingji@him.cas.cn); Zu Ye, E-mail: [yezuqscx@zju.edu.cn](yezuqscx@zju.edu.cn)  \nEdited by Zhiyuan Shen  \nPoly(ADP-ribose) glycosylhydrolase (PARG) is an enzyme involved in hydrolyzing the ribose–ribose bonds present in poly(ADPribose) (PAR), which are primarily found in the nucleus. Along with poly(ADP-ribose) polymerase, PARG regulates the level of PAR in cells, playing a crucial role in DNA maintenance and repair processes. Recent studies have revealed elevated levels of PARG in various cancers, such as breast, liver, prostate, and esophageal cancers, indicating a link to unfavorable cancer outcomes. PARG is a signiﬁcant molecular target for treating PAR-related cancers. This review provides a comprehensive overview of the physiological role of PARG and the development of its inhibitors, highlighting its potential as an innovative target for cancer treatment.  \nKeywords: PARG, PARG inhibitor, cancer therapy  \nIntroduction  \nADP-ribosylation, a dynamic and reversible post-translational modiﬁcation (PTM) similar to methylation, phosphorylation, and acetylation, occurs in two main forms: mono-ADP-ribosylation (MARylation) and poly-ADP-ribosylation (PARylation) (Li and Chen, 2014) . PARylation aﬀects numerous proteins across cellular compartments. It plays a critical role in DNA damage repair, transcriptional control, chromatin remodeling, genome stability, cell proliferation, apoptosis, and tumorigenesis (Miwa and Masutani, 2007 ; Frizzell et al., 2009) .  \nPoly(ADP-ribose) polymerase (PARP) serves as the posttranslational modifying enzyme found in the majority of eukaryotes and prokaryotes (Langelier et al., 2018) . It facilitates the ADP-ribose (ADPr) modiﬁcations of numerous nuclear proteins (Huang and Kraus, 2022) . PARP1, the archetypal member of the ADP-ribosylase superfamily, belongs to a group comprising at least 17 PARP-related enzymes that share homology with PARP1 (Schreiber et al., 2006) . Among these,  \nReceived August 27, 2024 . Revised November 22, 2024 . Accepted December 11, 2024.  \n© The Author(s) (2024) . Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, CEMCS, CAS.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/by](https://creativecommons.org/licenses/by)nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use,  \nplease contact [journals.permissions@oup.com](journals.permissions@oup.com)  \nPARP1, PARP2, PARP5A, and PARP5B are capable of synthesizing poly(ADP-ribose) (PAR) chains, while others mainly generate single ADPr units (Richard et al., 2021 ; van Beek et al., 2","cbCaip205kcfUSwy","https://ap.wps.com/l/cbCaip205kcfUSwy","pdf",1177720,14,"English","# Introduction\n## ADP-ribosylation and PARylation\n## PARP family overview\n## PARG function and PAR polymer degradation","[{\"question\":\"What role does PARG play in ADP-ribosylation?\",\"answer\":\"PARG hydrolyzes ribose–ribose bonds in poly(ADP-ribose) (PAR), helping regulate PAR levels in cells. This process is connected to DNA maintenance and repair.\"},{\"question\":\"Why are PARG inhibitors considered promising for cancer therapy?\",\"answer\":\"Elevated PARG levels have been reported in several cancers, and PARG is described as a significant molecular target for treating PAR-related cancers. Targeting PARG may affect PAR dynamics that support harmful cancer outcomes.\"},{\"question\":\"How does the PARylation cycle relate to PARG activity?\",\"answer\":\"PARylation formation and dissociation are dynamically regulated, with PAR being largely degraded by PARG at DNA damage sites. This transient regulation helps maintain cellular functions and genome stability.\"}]","Prospects for PARG inhibitors in cancer therapy | PDF",1790177303,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1b7498fa56006f9e3e7015875633ca8.webp",983,1269,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29dc123bd62ee6aa8d9d9c6739dc218a.webp",982,1268,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a4dc93c5318f2bbeb6b628c47ce896c.webp",981,1266,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cd2a4ee55e69bf2e26a96770b06ebde.webp",980,1265]